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Abstract
Identifying dietary modifications that potentiate the blood pressure (BP)-lowering effects of antihypertensive medications and that are
practical for free-living people may assist in achieving BP reduction goals. We assessed whether two dietary patterns were effective in low-
ering BP in persons on antihypertensive therapy and in those not on therapy. Ninety-four participants (38/56 females/males), aged 55·6 (SD
9·9) years, consumed two 4-week dietary regimens in random order (Dietary Approaches to Stop Hypertension (DASH)-type diet and low-
Na high-K (LNAHK) diet) with a control diet before each phase. Seated home BP was measured daily for the last 2 weeks in each phase.
Participants were grouped based on antihypertensive drug therapy. The LNAHK diet produced a greater fall in systolic BP (SBP) in those
on antihypertensive therapy (26·2 (SD 6·0) mmHg) than in those not on antihypertensive therapy (22·8 (SD 4·0) mmHg) (P¼0·036), and
this was greatest for those on renin–angiotensin system (RAS) blocker therapy (29·5 (SD 6·4) mmHg) (interaction P¼0·007). The fall in SBP
on the DASH-type diet, in those on therapy (overall 21·1 (SD 6·2) mmHg; renin–angiotensin blocker therapy 24·2 (SD 4·7) mmHg), was
not as marked as that observed on the LNAHK diet. Dietary modifications are an important part of all hypertension management regimens,
and a low-Na and high-K diet enhances the BP-lowering effect of antihypertensive medications, particularly those targeting the RAS.
Key words: Antihypertensive therapy: Dietary potassium: Dietary sodium: Home blood pressure: Salt
There is a continuous positive relationship between blood
pressure (BP) and CVD risk(1), with a doubling of risk
for each increment of 20/10 mmHg above 115/75 mmHg
(systolic BP (SBP)/diastolic BP (DBP))(1–3). Achieving BP
control is critical to improve cardiovascular prognosis in
hypertensives, and yet many of those on antihypertensive
therapy fail to achieve optimal BP levels(2). The reasons
for failure to achieve BP goals with antihypertensive medi-
cations are varied and include non-compliance with medi-
cation due to side effects, cost of the therapy and risk of
orthostatic hypotension(2). A multifaceted approach to
managing BP is required. Identifying dietary modifications
that potentiate the BP-lowering effects of antihypertensive
medications and that are practical for free-living people
may assist in achieving BP reduction goals.
The effectiveness of dietary modifications in reducing BP
in persons on antihypertensive therapy is not clear. High
salt intake is a major environmental factor that adversely
impacts on BP control(4). There have been conflicting
reports that have shown that individual nutrients (largely
Na) may either potentiate the BP-lowering effects of
some antihypertensive medications or have no additional
effect on BP. A synergistic effect of dietary salt restriction
and blockers of the renin–angiotensin system (RAS, angio-
tensin-converting enzyme inhibitors and angiotensin II
receptor antagonists) has been reported(5–9), but this is
not a consistent finding(10,11). Moreover, salt restriction can
be beneficial in people with BP resistance to angiotensin-
converting enzyme inhibition(12). Interestingly, Ca channel
blockers have been shown to have a greater hypo-
tensive effect when combined with a high Na intake and
compared with a contrasting low Na intake(13–15), although
this has not been an universal finding(16,17). The effects of
contrasting Na intakes (i.e. high and low) in those taking
b-adrenoceptor blockers have been shown to have no
effect on BP(18); however, at extremely low intakes of Na
*Corresponding author: Professor, C. A. Nowson, fax þ61 3 9244 6017, email nowson@deakin.edu.au
Abbreviations: BP, blood pressure; CD, control diet; DASH, dietary approaches to stop hypertension; DBP, diastolic BP; LNAHK, low-Na high-K; NO, no
therapy; OAH, other antihypertensive therapy; OD, DASH-type diet; RAS, renin–angiotensin system; SBP, systolic BP.
British Journal of Nutrition (2011), 105, 248–255 doi:10.1017/S0007114510003223
q The Authors 2010
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
(10 mmol/d), propranolol has been shown to cause a
greater BP reduction than at ‘usual’ Na intakes(19). A poss-
ible explanation for these conflicting observations could be
due to the influence of the background diet, which in most
instances is poorly described and/or uncontrolled. In
addition, a high-K diet has been shown to be effective in
controlling BP during tapering of antihypertensive medi-
cations down to 50 % of the original medication dose(20).
A limitation of many of these studies is that participants
were withdrawn from their usual BP medication regimen
and were all provided with a fixed dose of the test
drug(5–9), which does not reflect the heterogeneity of anti-
hypertensive medication regimens in free-living people.
The Dietary Approaches to Stop Hypertension (DASH)
study tested the efficacy of a comprehensive diet high in
fruits, vegetables and low-fat dairy products on BP in a
large intervention with all food provided to participants.
In that study, large falls in SBP and DBP were demon-
strated (11 and 5 mmHg in hypertensives; 5 and 3 mmHg
in normotensives); however, hypertensives who were on
antihypertensive medications were excluded(21). We have
previously reported on the beneficial effects of a DASH-
type diet (OD) and a low-Na high-K diet (LNAHK) on BP
in free-living people, who self-selected their own
food(22). In that study, we demonstrated that participants
were highly compliant with the dietary advice, and we
found (relative to a control diet) an overall significant fall
of 2 mmHg in SBP with the OD diet, and a greater fall of
4 mmHg SBP and 2 mmHg in DBP with the LNAHK diet.
These BP falls are meaningful at a population level(2) and
demonstrate the feasibility of these dietary patterns in
free-living individuals who prepared all their own meals.
The aim of this investigation was to examine whether the
LNAHK and the OD diets lowered BP in participants on
antihypertensive therapy than in those not on antihyper-
tensive therapy.
Methods
This investigation was undertaken as a subanalysis of the
cohort presented in our earlier report(22). Details of the par-
ticipants, study design, diets and dietary assessment,
anthropometry and biochemical assays have been reported
previously(22) and will be reported in brief here.
Participants
Participants were eligible if they were over 25 years of age
and had a BP $ 120 mmHg SBP or $ 80 mmHg DBP at
their second visit (mean of last three measurements) or
home BP $116 mmHg SBP or $ 78 mmHg DBP (mean of
7 d). Full details of recruitment and retention of the partici-
pants have been previously reported(22). Participants who
were taking antihypertensive medication were included,
provided they were willing to maintain their current level
of antihypertensive therapy. Participants were excluded if
they had a BP . 160 mmHg SBP and/or . 90 mmHg
DBP, had a cardiovascular event in the past 6 months,
had insulin-dependent diabetes, were on medications
such as Warfarin or Dilantin, ate their main meal outside
the home more than twice per week, drank more than
thirty alcoholic drinks per week, were planning to quit
smoking or change smoking habits or were unwilling to
cease taking dietary supplements (including vitamins) for
the duration of the study. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human subjects/
patients were approved by the Deakin University Human
Research Ethics Committee. Written informed consent
was obtained from all the subjects/patients.
Study design
All the participants were advised to follow two 4-week
dietary interventions, each preceded by a 2-week control
diet (CD) period, as reported previously(22). The diets
were consumed in random order which minimised the
interference of the time-dependent reduction in BP. Partici-
pants performed 24 h urine collections every 2 weeks.
The mean of two 24 h urine collections in each test diet
phase was used in the analysis. Ninety-four participants
completed the OD diet phase, and of this forty-three
participants also completed the LNAHK diet phase and
forty-eight participants completed a high-dairy diet
phase. We have previously reported that the high-dairy
diet had no significant effects on SBP or DBP(22).
Furthermore, for those on the high-dairy diet phase,
there was no significant difference in BP between those
who were not taking antihypertensive medication and
those who were taking antihypertensive medications
change in SBP (0·96 (SEM 0·62) mmHg (n 27) and 0·16
(SEM 0·64) mmHg (n 21), respectively; P¼0·384), and
therefore we have not included data on this diet.
Diets
The CD diet was a low-K, low-Ca diet. The OD diet, com-
pared with CD diet, was designed to be higher in K, Mg
and Ca, and lower in saturated fat, with a moderate
reduction in Na together with increased fish intake.
The OD diet was based on the United States DASH
study(21) and was rich in vegetables, fruits and reduced
fat dairy products, with increased fish, nuts and legumes
and a moderate Na intake (i.e. salt-reduced products
were recommended, # 120 mg/100 g). Compared with the
OD diet, the LNAHK diet was similarly plant based and
high in fruits and vegetables. The LNAHK diet (compared
with OD diet) was designed to be higher in K and Mg
with a greater reduction in Na intake, and as there were
no specific dietary recommendations for dairy products,
it was lower in Ca. To assist with achieving the Na targets
during the LNAHK diet phase, the participants were
Diet, antihypertensives and blood pressure 249
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provided with salt-free bread and margarine. During the
CD periods and all test diet phases, a maximum of four
caffeine-containing drinks (e.g. cola drinks, diet cola,
coffee and tea) and two standard alcoholic drinks were
permitted per day. The aim was to maintain body
weight for all the participants throughout the study.
Blood pressure and antihypertensive therapies
Home BP was measured using an automated BP
monitor (AND Model UA-767 or AND Model UA-767-PC,
A&D Company Limited, Tokyo, Japan) on the left arm,
and data were either directly downloaded via a
computer (Model UA-767-PC) or recorded manually
(Model UA-767). Subjects were trained to correctly apply
the cuff and instructed to take their BP measurements
alone at the same time of the day, after 5 min rest in a
quiet room, taking three measurements with 1 min interval
(mean of last two measurements on each day used
for analysis).
Of the ninety-four participants (thirty-eight females, fifty-
six males) who completed the OD diet phase, forty-two
were on antihypertensive therapy. There were no significant
differences in the baseline BP or urinary electrolytes of those
who were on antihypertensive therapy (n 42, mean SBP
130·8 (SD 10·7) mmHg; DBP 79·9 (SD 9·0) mmHg) and
those who were not on therapy (n 52, SBP 128·3
(SD 11·8) mmHg; DBP 81·1 (SD 8·4) mmHg)(22). The range
of medication types were twenty-two participants on
single therapy: b-blocker (n 2); angiotensin-converting
enzyme inhibitor (n 3); angiotensin II receptor antagonist
(n 12); diuretic (n 1); Ca channel blocker (n 4). A further
twelve were on combination therapy either with a single
tablet (n 4) or with dual tablets (n 8), and eight were
taking a combination of three drugs. Of the forty-three
participants who followed the LNAHK diet, twenty-three
were not on antihypertensive therapy and twenty were on
antihypertensive therapy including eleven participants on
single therapy: b-blocker (n 1); angiotensin-converting
enzyme inhibitor (n 1); angiotensin II receptor antagonist
(n 6); Ca channel blocker (n 3). The remaining nine partici-
pants were on combination therapy either with a single
tablet (n 4) or with dual tablets (n 2) or a combination of
three drugs (n 3). For this analysis, the participants were
categorised into one of the three medication groups: (1)
no therapy (NO); (2) RAS blockade, which included
angiotensin-converting enzyme inhibitor and angiotensin
II receptor antagonists as monotherapies; (3) other
antihypertensive therapies (OAH), including single and
combination therapies (Table 1).
Statistical analysis
Data were analysed using SPSS for WINDOWS (version
17.0 SPSS, Inc., Chicago, IL, USA). ANOVA was used to
assess the difference in BP between the control diet and
test diet phases (within-group factor) across the medication
groups (between-group factor), i.e. a separate analysis was
completed for the each test diet phase, compared to their
respective control diet period. A Sidak’s t test was used
for post hoc analysis. One-way ANOVA was used to evalu-
ate the difference in the changes in BP between the OD
and LNAHK diet phases. P,0·05 was considered to be sig-
nificant. Data are expressed as means and standard
deviations.
Results
Baseline characteristics when grouped by class of
antihypertensive therapy
Table 2 shows the baseline characteristics of the partici-
pants across the three medication groups (NO, RAS and
OAH). The three groups were well matched for baseline
SBP and DBP and urinary Na and K (Table 2). Participants
in the NO group were younger (mean 52·1 (SD 10·2) years)
than the participants in the other two medication groups
(RAS 58·7 (SD 8·8) years; OAH 61·7 (SD 6·4) years). Partici-
pants in the RAS group had a modestly greater BMI by
approximately 10 % than the participants in the NO
group (P¼0·012).
Dietary compliance: no antihypertensive therapy
v. antihypertensive therapy
Dietary compliance was assessed by comparing the urinary
excretion during the dietary intervention period (average
of two 24 h urine excretion in weeks 2 and 4) with the
Table 1. Class of antihypertensive therapy in each of two test diet
groups
Antihypertensive therapy *
OD
(n)
LNAHK
(n)
No therapy 52 23
RAS
ACEI 3 1
AT1 blocker 12 6
Other antihypertensive therapy
Ca channel blocker 4 3
Ca channel blocker, diuretic 1 0
Ca channel blocker þ AT1 blocker 2 2
Ca channel blocker, ACEI, diuretic 1 1
Ca channel blocker þ (AT1 blocker þ diuretic) 3 1
b-Adrenoceptor blocker 2 1
Diuretic 1 0
(AT1 blocker þ diuretic) 2 0
(ACEI þ diuretic) 2 2
ACEI, diuretic 2 1
Diuretic, b-adrenoceptor blocker 1 0
Diuretic, central acting agent 1 1
AT1 blocker, b-adrenoceptor blocker 1 0
ACEI diuretic, b-adrenoceptor blocker 2 1
ACE-I (ACEI þ diuretic) 1 0
Diuretic (ACEI þ diuretic) 1 0
OD, DASH-type die; LNAHK, low-Na high-K; RAS, renin–angiotensin system
blockade; ACEI, angiotensin-converting enzyme inhibitor; AT1, angiotensin II
receptor subtype 1.
* Combination medication in parenthesis indicates a single fixed combination
medication; multiple different medications are separated by a comma.
C. E. Huggins et al.250
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preceding CD period (Table 3). Urinary Na fell by approxi-
mately twice as much in the LNAHK diet phase than in the
OD diet phase (P¼0·01), and there was no significant
difference between those not on antihypertensive
therapy (LNAHK 263·1 (SD 63·7) mmol/d; OD 229·1 (SD
58·9) mmol/d) and those on antihypertensive therapy (i.e.
RAS þ OAH groups) (LNAHK 282·2 (SD 57·5) mmol/d;
OD 235·3 (SD 65·5) mmol/d). Urinary K and Mg increased
with both the test diets by similar amounts and were not
significantly different across the medication groups.
Taken together, these data indicate that compliance with
dietary advice was similar across the groups.
Comparison of blood pressure responses to test diets:
antihypertensive therapy v. no therapy
The BP distribution of those not taking antihypertensive
therapy and those on therapy was similar at baseline.
The LNAHK diet produced the greatest fall in SBP in
those on antihypertensive therapy (26·2 (SD 6·0) mmHg
SBP) than in those not on therapy (22·8 (SD 4·0) mmHg
SBP; P¼0·036 interaction Fig. 1(a)). Overall, the fall in
DBP on the LNAHK diet was not significantly different
between those on therapy and those not on therapy
(P¼0·094 interaction) (Fig. 1(b)). Overall, the OD diet
did not significantly lower SBP (21·1 (SD 6·2) mmHg) for
those on therapy, relative to the preceding CD phase. For
those not on therapy, the LNAHK and OD diets lowered
SBP by a similar magnitude (LNAHK 22·8 (SD 4·0) mmHg
v. OD 22·4 (SD 4·4) mmHg SBP; Fig. 1(a)), relative to the
CD period.
Comparison of test diets on blood pressure responses for
classes of antihypertensive therapy
Those on antihypertensive therapy were divided into two
groups: those on RAS therapy and those on other therapies
Table 2. Baseline characteristics of participants categorised by antihypertensive therapy
(Mean values and standard deviations)
No therapy
(n 52)
RAS therapy
(n 15)
Other antihyperten-
sive therapy (n 27)
One-way
ANOVA
Mean SD Mean SD Mean SD P
Women/men, (n/n) 20/32 6/9 12/15
Age range (years) 29–72 49–81 48–74
Age (years) 52·1* 10·2 58·7 8·8 61·7 6·4 ,0·001
Wt (kg) 82·6 13·3 93·1* 16·8 81·9 9·3 0·019
BMI (kg/m2) 28·2 3·6 31·1† 4·6 29·5 3·3 0·033
Home systolic BP (mmHg) 128·3 11·8 131·6 9·3 130·3 11·5 0·538
Home diastolic BP (mmHg) 81·1 8·4 77·9 9·4 81·1 8·7 0·412
Pulse (beats/min) 67·0 8·2 68·4 8·9 67·3 9·3 0·854
Urinary Na (mmol/d)‡ 142·1 49·9 167·5 37·0 154·7 54·6 0·189
Urinary K (mmol/d)‡ 76·0 25·0 86·4 27·5 75·3 21·3 0·309
Urinary Na:K 2·0 0·8 2·2 1·0 2·2 1·0 0·679
Urinary Ca (mmol/d)‡ 3·9 1·8 3·6 2·4 3·1 2·3 0·287
Urinary Mg (mmol/d)‡ 4·3 1·4 4·5 2·1 4·5 1·1 0·744
RAS, renin–angiotensin system blockade; BP, blood pressure.
* Mean values were significantly different from when compared with that of all other groups (P,0·05, post hoc Sidak’s t test).
† Mean values were significantly different from when compared with that of no medication group (P,0·05, post hoc Sidak’s t test).
‡ To convert mmol/d into mg/d: multiply by 23 for Na, 39 for K+ and 40 for Ca2+.
Table 3. Response of participants to low-Na high-K (LNAHK) diet categorised by antihypertensive therapy group
(Mean values and standard deviations)
No therapy (n 23) RAS therapy (n 7) All other therapy (n 13)
CD LNAHK CD LNAHK CD LNAHK
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Urinary Na (mmol/d)‡ 133·9 53·2 61·9 34·0 133·6 38·9 48·1 23·1 143·9 69·7 59·5* 44·2
Urinary K (mmol/d)‡ 68·9 26·7 102·2 21·2 75·1 13·6 123·2 19·8 71·6 19·0 104·2* 27·9
Urinary Ca (mmol/d)‡ 3·4 2·0 2·8 1·4 3·3 2·5 2·4 1·6 2·8 1·0 2·4* 2·0
Urinary Mg (mmol/d)‡ 4·1 1·5 4·8 1·5 4·6 3·4 5·3 1·8 4·3 2·0 4·4* 1·4
Urinary Na:K 2·1 1·1 0·7 0·5 1·8 0·4 0·4 0·3 2·1 1·5 0·7* 0·9
Wt (kg) 83·7 13·7 83·3 13·8 87·4 15·7 86·5 15·8 81·6 7·4 81·5* 7·0
Pulse (bpm) 65·7 7·1 65·5 7·3 70·1 6·2 71·6 7·8 69·1 6·2 69·0 6·1
Systolic BP (mmHg) 126·3 10·4 123·4 9·8 132·7 12·1 123·2 8·6 127·7 8·8 123·3*† 8·1
Diastolic BP (mmHg) 78·5 5·6 77·4 5·6 82·2 3·2 78·1 7·5 81·9 6·7 79·4* 6·7
RAS, renin–angiotensin system blockade; CD, control diet; bpm, beats/min; BP, blood pressure.
* Repeated measures ANOVA, between-group factor is antihypertensive medication groups; within-group factor is diet (CD and LNAHK; P,0·05).
† Repeated measures ANOVA, between-group factor is antihypertensive medication groups; within-group factor is interaction (diet £ medication group; P,0·05).
‡ To convert mmol/d into mg/d, multiply by 23 for Na, 39 for Kþ, 40 for Ca2þ and 24·3 for Mg.
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(OAH). During the CD period, there were no significant
differences in SBP or DBP across the three medication
groups (Tables 3 and 4) . The LNAHK diet lowered SBP
(relative to CD) across all the medication groups
(ANOVA, P¼0·014). Overall, the fall in BP during the
LNAHK diet phase was greater than during the OD diet
phase by SBP 21·1 (SD 4·6), 23·8 (SD 5·7) and 27·6 (SD
8·0) mmHg for NO, RAS and OAH, respectively (ANOVA
P,0·001); and DBP 20·3 (SD 3·9), 22·1 (SD 3·4), 24·6
(SD 6·0) mmHg for NO, RAS and OAH, respectively (n 43,
repeated measures ANOVA P¼0·05).
The LNAHK diet resulted in a greater fall in SBP in the RAS
group (29·5 (SD 6·4) mmHg) than in the NO medication
group (22·8 (SD 4·0) mmHg) (P¼0·007) Fig. 2(a)). This
difference remained significant (P¼0·015, ANCOVA) when
controlling for the change in Na excretion (between CD
and LNAHK diets). This difference was not observed with
the OD diet (NO group (22·4 (SD 4·4) mmHg, v. RAS
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Fig. 1. Blood pressure (BP) response to test diets in those not on antihypertensive therapy and those on therapy. Change in home-measured BP relative to control
diet phase during the low-sodium high-potassium diet phase (a) systolic BP (b) diastolic BP, and during the DASH-type diet (OD) phases (c) systolic BP and
(d) diastolic BP. (2 ) Not on antihypertensive therapy; (þ) taking antihypertensive therapy. Data are means and standard deviations. * Mean values were
significantly different ANOVA, P,0·05 interaction (diet £ medication group).
Table 4. Response of participants to DASH-type diet (OD) diet categorised by antihypertensive therapy group
(Mean values and standard deviations)
No therapy (n 52) RAS therapy (n 15) All other therapy (n 27)
CD OD CD OD CD OD
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Urinary Na (mmol/d)§ 143·4 47·6 114·3 51·6 166·6 75·6 119·8 46·9 139·8 47·4 118·6* 49·7
Urinary K (mmol/d)§ 67·6 20·7 100·3 27·8 66·5 22·6 115·4 26·9 56·8 17·3 92·8* 20·6
Urinary Ca (mmol/d) 3·7 2·1 3·8 1·8 3·9 3·1 3·3 2·5 2·9 1·8 3·3 3·1
Urinary Mg (mmol/d)§ 4·0 1·6 4·7 1·5 3·7 1·8 4·9 2·8 3·7 0·9 4·7* 1·3
Urinary Na:K 2·1 0·9 1·2 0·7 2·5 0·7 1·0 0·4 2·3 1·1 1·3* 0·6
Wt (kg) 81·6 13·0 81·7 13·0 91·1 16·9 90·7 17·2 82·4 8·5 82·1‡ 9·1
Pulse (bpm) 66·8 8·6 66·8 8·2 67·2 8·8 68·1 9·3 65·6 6·4 67·3* 6·7
Systolic BP (mmHg) 127·8 11·8 125·4 10·0 129·5 10·6 125·3 8·9 124·6 10·2 125·3*† 9·6
Diastolic BP (mmHg) 80·6 8·1 79·9 7·8 78·2 10·9 76·8 9·7 77·6 8·3 78·3 8·9
RAS, renin–angiotensin system blockade; CD, control diet; bpm, beats per min; BP, blood pressure.
* Repeated measures ANOVA, between-group factor is antihypertensive medication groups within-group factor is diet (CD and OD) (P,0·05).
† Repeated measures ANOVA, between-group factor is antihypertensive medication groups interaction (diet £ medication group) (P,0·05).
‡ Repeated measures ANOVA, between-group factor is antihypertensive medication groups (P,0·05).
§ To convert mmol/d into mg/d, multiply by 23 for Na, 39 for Kþ, 40 for Ca2þ and 24·3 for Mg.
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group (24·2 (SD 4·7) mmHg, P¼0·533). The changes in DBP
were not significantly different across the diet–medication
groups (LNAHK P¼0·199; OD P¼0·859), although a similar
pattern was followed to SBP (Fig. 2(b) and (d)).
Discussion
The major finding of the present study was that in free-living
persons on antihypertensive therapy, dietary advice to
follow a LNAHK diet produced a greater fall in BP in
those on antihypertensive therapy (regardless of medication
type) than in those not on antihypertensive therapy.
Furthermore, the LNAHK diet lowered BP more than
the DASH-type dietary pattern (SBP 26·2 (SD 6·0) v. 21·1
(SD 6·1) mmHg) in those on antihypertensive therapy.
Both the dietary patterns reduced systolic pressure to a
greater degree in those on RAS blockers (compared with
all others), and the fall in systolic pressure was 5 mmHg
greater with the LNAHK diet than with the DASH-type
diet. For those not on antihypertensive therapy, SBP was
lowered by a similar extent under both the dietary patterns
(approximately 2·6 mmHg). These findings are clinically rel-
evant because it has been demonstrated that dietary advice
to lower Na and K is feasible and effective in free-living
persons on a range of different antihypertensive therapies.
In our earlier report(22), where we grouped all partici-
pants together, it was observed that the LNAHK diet
produced a greater fall in SBP of 2·6 mmHg than the OD
diet. In the present study, we found that for those not on
therapy, the LNAHK and OD diets lowered BP by a similar
degree (approximately 22·4 and 22·8 mmHg, respect-
ively). The ratio of Na to K (Na:K) during both the test
diet phases was close to 1:1 (OD 1·2:1 v. LNAHK 0·7:1),
which was approximately half of the ratio during the CD
period. Recently, it has been reported that Na:K may be
a stronger predictor of CVD than either Na or K alone(23)
and an important factor in BP regulation(23–25).
In the present study, 45 % of the cohort were on antihy-
pertensive therapy. Compared with the OD diet, the
LNAHK diet appeared to be a more favourable dietary pat-
tern for BP reduction (SBP and DBP) for those on antihy-
pertensive drug therapies. The LNAHK diet produced a
marked potentiating effect on BP reduction across each
of the medication groups, and the magnitude of this
effect was greater in those on antihypertensive therapy
than in those not on therapy. It has been reported that
those with established hypertension are more likely to
respond with a BP reduction on a reduced Na intake.
This may in part explain the greater fall in BP, in those
with established hypertension, when following the
LNAHK diet. The mechanism(s) for heightened salt sensi-
tivity remains undetermined(26), and despite controlling
BP with antihypertensive medication, this hyperrespon-
siveness to salt persists.
An important finding of the present study was that those
on OAH, which included those on diuretics and Ca channel
blockers, exhibited a fall in BP with a LNAHK diet, and that
the difference in the fall in BP was greater than the fall
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Fig. 2. Blood pressure (BP) response to test diets in those not on antihypertensive therapy and those on RAS monotherapy. Change in home measured BP
relative to control diet phase during the low-sodium high-potassium diet (a) phase, systolic (b) diastolic BP, and the DASH-type diet (OD) phases (c) systolic
BP and (d) diastolic BP. NO, not taking antihypertensive medication; RAS, renin–angiotensin system blockade as monotherapy. Data are means and standard
deviations. * Mean values of RAS is significantly different to NO group (P,0·05, ANOVA).
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observed with the DASH-type diet (a difference of
27·6 mmHg). Previous studies have shown that Na restric-
tion does not potentiate the BP-lowering effects of Ca chan-
nel blockers(16,17). Chrysant et al.(8) demonstrated that in
those taking a dihydropyridine Ca channel blocker (isradi-
pine), the magnitude of BP reduction (relative to baseline)
was greater during a high Na intake (200–250 mmol/d for
4 weeks) than during a low Na intake (50–80 mmol/d for
4 weeks). It is possible that the difference in the findings
between the present study and previous studies is due to
the context in which Na restriction occurs (e.g. when K
levels are low), as this may be as crucial as the restriction
itself. In the study of Chrysant et al.(8), the levels of K
excretion were not reported, and therefore it is not known
if the BP-lowering effect of isradipine occurred on the back-
ground of a high-K diet (or a Na:K of # 1:1). Overall, our
findings do suggest an important role for dietary modifi-
cations to lower Na and increase K to favourably lower BP
in all those on antihypertensive drug therapies, although
hypertension requiring multiple therapy may be less sensi-
tive to the BP-lowering effects of diet.
It cannot be determined from the present study that
whether the LNAHK diet is potentiating the BP effect of
the antihypertensive medication via an increased effective-
ness of the medication regime or via an independent
mechanism that acts synergistically with the BP medication,
or both. The interplay between Na, Ca and the RAS in the
regulation of arterial BP remains unclear, and elucidation
of the molecular mechanisms that cause hypertension con-
tinues to be an important area of research(27).
The OD diet was effective in lowering BP in those taking
RAS blockade; however, this was not as marked as the
LNAHK diet, and the OD diet did not lower BP in those
taking combination therapies or monotherapies other
than RAS blockade (e.g. Ca channel blockers or b-adreno-
ceptor blockers). This is an interesting observation that
should be followed up in larger controlled studies, particu-
larly given that the DASH-type diet is now recommended
in hypertension management by the American Heart
Association. To our knowledge, there has only been one
other study that has examined the DASH-type dietary
pattern in persons taking antihypertensive medication(28).
Kirpizidis et al.(28) reported no additive effect of a low Na
DASH-type diet in combination with candesartan (angio-
tensin II receptor inhibitor) in hypertensives, than with
candesartan alone, after 16 weeks of treatment. This
contrasts with the present study and may be attributed to
insufficient power to detect a difference in BP with their
sample size. Moreover, it is not clear from the report of
Kirpizidis et al.(28) that whether dietary compliance was
achieved, as no defined measures of dietary compliance
were reported.
The strengths of the present study were that dietary com-
pliance was assessed by 24 h urine collection and home BP
was measured. Home BP is becoming the BP measurement
of choice as it is associated with less variability and therefore
enhances the sensitivity to detect small changes in BP(22,29,30)
with a smaller sample size. A limitation of the present study is
that participants were classified post hoc, and therefore the
sample size across the groups was unbalanced; however,
the range of different medication regimens reflects the het-
erogeneity in treatment of hypertension in the real world.
Although the present study had limited power (between
50 and 65 %) to detect a significant difference in SBP for
each dietary regimen across all the medication groups, our
findings do indicate that dietary modifications, particularly
a LNAKH diet pattern is a useful adjunct treatment for
hypertension.
In summary, a LNAHK diet reduced SBP in all the groups,
particularly in those with established hypertension. The
DASH-type diet selectively lowered BP in those not on
therapy and those on RAS monotherapy, but the falls were
less than with the LNAKH diet. The combination of RAS
blockade (monotherapy) with either dietary pattern rep-
resents a more effective treatment regimen for BP reduction
than RAS blockade alone. It is important that any dietary
advice is applicable and sustainable for free-living individ-
uals. Thus, a limitation of thepresent study is that participants
were provided with a salt-free bread to achieve the low Na
intake (and a Na:K ratio # 1:1). The increased availability
of bread with a lower Na content coupled with increased
consumption of more fruits and vegetables to increase K
intake would assist in controlling BP, particularly in those
taking antihypertensive medication. The present study
highlights that dietary modifications are an important part
of all hypertension management regimens, and that
reducing dietary Na and increasing dietary K enhances the
BP-lowering effect of antihypertensive drug therapies.
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